Regulated information

2010 annual earnings

Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements.

2010 Revenues grow 11.8%, driven by organic growth

The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth.

2018 sales: up 3.2% to €367.9 million

9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES

Combined ordinary and extraordinary general meeting May 21, 2019

The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin.

European launch of new Nsaid Cimalgex®

Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs.

First half 2019 results

At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements.

Forcyl®: european launch of new drug

Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection.

Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%)

At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements.

International expansion and new product launches

Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011.

Jacques du Puy appointed Vétoquinol Managing Director

Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment
of Jacques du Puy as Managing Director.